Drug Details
| General Information of the Drug (ID: DR0459) | ||||
|---|---|---|---|---|
| Name |
Albiflorin
|
|||
| Synonyms |
Albiflorin; 39011-90-0; Alibiflorin; Q63399047; 7-Oxatricyclo[4.3.0.03,9]nonan-8-one,9-[(benzoyloxy)methyl]-1-(b-D-glucopyranosyloxy)-4-hydroxy-6-methyl-,(1R,3R,4R,6S)-; CHEBI:132793; HY-N0037; MFCD29477681; ZINC38143679; AKOS032948342; CS-3643; NCGC00169374-01; NCGC00169374-02; AS-75074; C17457; BRD-K76724902-001-01-6; [(1R,3R,4R,6S,9S)-1-(beta-D-glucopyranosyloxy)-4-hydroxy-6-methyl-8-oxo-7-oxatricyclo[4.3.0.0(3,9)]nonan-9-yl]methyl benzoate; [(1R,3R,4R,6S,9S)-4-hydroxy-6-methyl-8-oxo-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7-oxatricyclo[4.3.0.03,9]nonan-9-yl]methyl benzoate; [(1R,3R,4R,6S,9S)-4-HYDROXY-6-METHYL-8-OXO-1-{[(2S,3R,4S,5S,6R)-3,4,5-TRIHYDROXY-6-(HYDROXYMETHYL)OXAN-2-YL]OXY}-7-OXATRICYCLO[4.3.0.0(3),?]NONAN-9-YL]METHYL BENZOATE
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Chronic obstructive pulmonary disease [ICD-11: CA22] | Investigative | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C23H28O11
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC12CC(C3CC1(C3(C(=O)O2)COC(=O)C4=CC=CC=C4)OC5C(C(C(C(O5)CO)O)O)O)O
|
|||
| InChI |
1S/C23H28O11/c1-21-8-13(25)12-7-23(21,33-19-17(28)16(27)15(26)14(9-24)32-19)22(12,20(30)34-21)10-31-18(29)11-5-3-2-4-6-11/h2-6,12-17,19,24-28H,7-10H2,1H3/t12-,13+,14+,15+,16-,17+,19-,21-,22-,23-/m0/s1
|
|||
| InChIKey |
QQUHMASGPODSIW-ICECTASOSA-N
|
|||
| CAS Number |
CAS 39011-90-0
|
|||
| ChEBI ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug | ||||||
| Paeoniflorin | Paeonia lactiflora | Click to Show/Hide the Molecular Data of This NP | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | Mice were exposed to X-ray radiation (400 Roentgen), and both mice and rabbits were intraperitoneally injected with cyclophosphamide (100.0 mg/kg) and cytarabine chloride (92.7 mg/kg), respectively, for 3 days to induce myelosuppression. | |||||
| Experimental
Result(s) |
These results substantiate the marked therapeutic effects of CPA to ameliorate myelosuppression induced by radio and chemotherapy. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Caspase-3 (CASP3) | Molecule Info | [3] | |
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | p53 signaling pathway | |||
| 3 | Apoptosis | |||
| 4 | Natural killer cell mediated cytotoxicity | |||
| 5 | TNF signaling pathway | |||
| 6 | Serotonergic synapse | |||
| 7 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 8 | Alzheimer's disease | |||
| 9 | Parkinson's disease | |||
| 10 | Amyotrophic lateral sclerosis (ALS) | |||
| 11 | Huntington's disease | |||
| 12 | Epithelial cell signaling in Helicobacter pylori infection | |||
| 13 | Pertussis | |||
| 14 | Legionellosis | |||
| 15 | Toxoplasmosis | |||
| 16 | Amoebiasis | |||
| 17 | Tuberculosis | |||
| 18 | Hepatitis B | |||
| 19 | Herpes simplex infection | |||
| 20 | Pathways in cancer | |||
| 21 | Viral carcinogenesis | |||
| 22 | Proteoglycans in cancer | |||
| 23 | MicroRNAs in cancer | |||
| 24 | Colorectal cancer | |||
| 25 | Viral myocarditis | |||
| NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
| 2 | IL2 Signaling Pathway | |||
| 3 | IL4 Signaling Pathway | |||
| Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
| 2 | FAS signaling pathway | |||
| 3 | Huntington disease | |||
| 4 | CCKR signaling map ST | |||
| Pathway Interaction Database | LPA receptor mediated events | Click to Show/Hide | ||
| 2 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| 3 | FAS (CD95) signaling pathway | |||
| 4 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
| 5 | Posttranslational regulation of adherens junction stability and dissassembly | |||
| 6 | p75(NTR)-mediated signaling | |||
| 7 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
| 8 | Caspase Cascade in Apoptosis | |||
| 9 | Syndecan-2-mediated signaling events | |||
| Reactome | SMAC binds to IAPs | Click to Show/Hide | ||
| 2 | SMAC-mediated dissociation of IAP:caspase complexes | |||
| 3 | Apoptotic cleavage of cellular proteins | |||
| 4 | Degradation of the extracellular matrix | |||
| 5 | NADE modulates death signalling | |||
| 6 | Activation of DNA fragmentation factor | |||
| 7 | Caspase-mediated cleavage of cytoskeletal proteins | |||
| WikiPathways | DNA Damage Response | Click to Show/Hide | ||
| 2 | SIDS Susceptibility Pathways | |||
| 3 | Apoptosis Modulation by HSP70 | |||
| 4 | MAPK Signaling Pathway | |||
| 5 | Copper homeostasis | |||
| 6 | FAS pathway and Stress induction of HSP regulation | |||
| 7 | Signaling by Hippo | |||
| 8 | Apoptosis | |||
| 9 | Amyotrophic lateral sclerosis (ALS) | |||
| 10 | Spinal Cord Injury | |||
| 11 | BDNF signaling pathway | |||
| 12 | Integrated Pancreatic Cancer Pathway | |||
| 13 | Oncostatin M Signaling Pathway | |||
| 14 | Parkinsons Disease Pathway | |||
| 15 | Corticotropin-releasing hormone | |||
| 16 | Allograft Rejection | |||
| 17 | AGE/RAGE pathway | |||
| 18 | TNF alpha Signaling Pathway | |||
| 19 | Prostate Cancer | |||
| 20 | Alzheimers Disease | |||
| 21 | TWEAK Signaling Pathway | |||
| 22 | Integrated Breast Cancer Pathway | |||
| 23 | Signalling by NGF | |||
| 24 | Integrated Cancer pathway | |||
| 25 | Regulation of Apoptosis | |||
| 26 | Intrinsic Pathway for Apoptosis | |||
| 27 | Apoptotic execution phase | |||
| 28 | Apoptosis Modulation and Signaling | |||
| 29 | miRNA Regulation of DNA Damage Response | |||
